Hokkaido University leverages BostonGene’s AI-powered platform to advance precision oncology US-based BostonGene, developer of the leading AI foundation model f
Hokkaido University is expanding its research collaboration with BostonGene, a US-based company specializing in AI for tumor and immune biology. This partnership aims to accelerate advancements in precision oncology by utilizing BostonGene's AI-powered platform. The collaboration focuses on leveraging AI to better understand cancer biology and develop more targeted treatments. AI
IMPACT This collaboration could lead to new AI-driven insights and treatments in precision oncology.